Daily filing brief

10 Most Important Filings — 12 August 2026

A concise list of today's most consequential exchange filings, selected for relevance and impact.

  1. Apollo Hospitals Enterprise Ltd3:22 am IST

    Apollo Hospitals Q1 FY27: Revenue up 21%, EBITDA up 28%, PAT up 34%, HealthCo composite scheme outlined

    Business overview

    • Core business spans Healthcare Services, Diagnostics & AHLL, and Digital Health & Pharmacy Distribution via Apollo HealthCo.
    • AHLL's Mother & Child and Fertility units to combine into a major maternity platform.
    • Apollo HealthCo is the omni-channel platform integrating digital and offline healthcare services.

    Operational highlights

    • Commissioned five new hospitals in the last two quarters.
    • Total census beds after expansion ~14,100.
    • Current beds at Q1FY27: 9,857.
    • Expansion plan adds about 1,000 census beds; total project cost ₹11,150 cr, ₹7,500 cr remaining.
    • Geographic expansion across Pune, Delhi, Hyderabad, Kolkata, and other Tier-1/Tier-2 cities.
    • Of 1,000 beds, 380 operational; 620 to be activated in 12–18 months.

    Financial performance

    • Consolidated revenue ₹70,435 mn; YoY growth 21%.
    • Consolidated EBITDA ₹10,920 mn; margin 15.5%.
    • PAT ₹5,805 mn; growth 34%.
    • ROCE 28.5% in Q1FY27.
    • Hospital segment occupancy 70% established units; average revenue per in-patient ₹186,630.

    Capital structure & liquidity

    • Cash and equivalents ₹23,560 mn; liquid funds ₹18,555 mn.
    • Consolidated net debt ₹7,481 mn.

    Strategic priorities & outlook

    • Composite scheme approved; demerger of OCP and Apollo 24x7 into NewCo; amalgamation with Keimed.
    • Listing expected by Q4 FY27.
    • Target run-rate revenue ₹250 bn; EBITDA margin 6.5–7.0%.
    • Plan bolt-on acquisitions in Tier-1 cities.

    Risks & mitigation

    • Execution risk in phased 1,000-bed expansion.
    • Integration risk from HealthCo demerger and amalgamation.
    • One-time network investment impacting margins.

    Governance & leadership

    • Shareholder approvals secured for composite scheme; NewCo listing.
    • NewCo to be Indian-owned and controlled (IOCC) post approvals.
    • Automatic listing of NewCo; AHEL shareholders directly participate.
    • Post-merger listing expected by Q4 FY27.
    Read the original filing
  2. Ola Electric Mobility Ltd2:41 pm IST

    MHI revises ACC PLI timelines for Ola Electric; secures full five-year incentives through CY2031, up to ₹7,240 crore

    PLI timeline revision and incentives

    • MHI approves revised ACC PLI timelines for Ola Cell Technologies, securing five-year PLI window through CY2031.
    • Cumulative PLI incentives up to ₹7,240 crore; disbursements quarterly beginning next quarter.
    • Current installed cell capacity at Ola Electric: 2.5 GWh.
    • Additional 3.5 GWh under installation; total 6 GWh by end of current quarter.
    • Five-year window extends original timeline by two years.
    • Roadmap includes Shakti and Mahashakti energy products; broader energy platform underway.
    Read the original filing
  3. Lupin Ltd11:13 pm IST

    Lupin posts record Q1 FY2027 revenue and EBITDA; US growth solid, full-year EBITDA guidance around 25%.

    Financial Performance

    • Q1 FY27 revenue from operations: INR 8,277 crores; EBITDA ex-forex/other income: INR 2,464 crores.
    • Revenue grew 32% YoY; EBITDA grew 50% YoY; 16th consecutive YoY growth.
    • Gross margin at 74.6% in Q1; up 330 bps vs Q1 FY26.
    • EBITDA margin was 30% in Q1; full-year target around 25%.
    • R&D spend 7.4% of sales; INR 608 crores.
    • Other operating income: INR 60 crores; down 43% YoY due to lower export benefits.
    • Operating working capital: INR 8,260 crores; 90 days of net working capital.
    • Net cash: INR 2,831 crores as of 30 June 2026; 4,636 crores as of 31 March 2026.
    • ROCE: 29.5%; FY26 was 28.4%.
    • ESG progress: 41% GHG reduction, 45% water recycling; TIME sustainability list recognition.

    Geography & Segments

    • U.S. sales: USD 366 million in Q1; CC growth 30% YoY.
    • FY27 U.S. revenue target: USD 1.1–1.2 billion.
    • India sales: INR 2,380 crores; 13.9% YoY; core prescription growth 15.1%.
    • Volume growth in India: 6.1%; chronic share ~67% of portfolio.
    • Other Developed Markets: INR 1,149 crores; 14% of sales; YoY +48%; Europe +83%.
    • Emerging Markets: INR 990 crores; YoY +52%; Brazil +117% local currency.

    Pipeline & Product Launches

    • Pegfilgrastim launch expected in H2 FY27; 505(b)(2) Dalbavancin in pipeline.
    • Nasal Fluticasone spray; Epinephrine nasal spray; Raltegravir; Eribulin; Diazepam nasal spray in FY27.
    • FY28: Apixaban 505(b)(2); Diazepam nasal; Epinephrine nasal; iron sucrose; Saxenda; Ivacaftor FTF.
    • FY29: Spiriva Respimat filing; Etanercept; potential P4-related timing.
    • Xywav is a FY33 product; MDI capacity is fungible across products.

    Guidance & Outlook

    • Near-term US headwinds from Tolvaptan and Mirabegron; growth moderates.
    • FY27 US revenue guidance anchored at USD 1.1–1.2 billion.
    • Full-year EBITDA margins expected around 25%.
    • R&D spend 7.4% of sales; ETR expected 27–28%.
    • US growth to resume from FY28; 50+ US products in pipeline.

    Risks & Watchpoints

    • US competition in Tolvaptan and Mirabegron could pressure margins.
    • Geopolitical headwinds and FX volatility remain risk factors.
    • Export benefits under PLI schemes declined; impact on Other Operating Income.
    • FDA EIRs received for Ankleshwar and Somerset; Pithampur remediation ongoing.
    Read the original filing
  4. Black Box Ltd3:50 am IST

    Black Box reports Q1 FY27 revenue ₹1,719 crore, backlog US$949 million; FY27 orders guidance US$1.3-1.5B

    Financial highlights

    • Q1 FY27 revenue ₹1,719 crore, up 24% YoY
    • EBITDA ₹160 crore, margin 9.3%, up 90 bps
    • PAT ₹56 crore, up 18% YoY
    • Order backlog US$949 million (~₹8,986 crore), up 83% YoY
    • New orders during quarter US$339 million (~₹3,208 crore)

    Backlog and bookings outlook

    • Backlog at quarter-end US$949 million; project-led backlog up ~50% QoQ
    • FY27 order bookings guidance US$1.3-1.5 billion (growth ~32-45% vs FY26)
    • End-FY27 backlog target US$1.3-1.4 billion (up 65-75% YoY)

    Strategic developments

    • New global hyperscaler order worth US$131 million
    • Gigawatt-scale data centre programs; India-origin AI-led provider
    • Plan to hire ~3,000 professionals by FY30, mainly in the U.S.
    • Aims to reach US$2 billion revenue by FY30

    Market and execution momentum

    • Demand broad-based across financial services, healthcare, public services, retail
    • Approximately 300 strategic enterprise accounts engaged
    Read the original filing
  5. Aster DM Quality Care Ltd8:12 pm IST

    Aster DM Quality Care Q1 FY27: revenue up 20%, EBITDA up 30%, synergy-led margin path to 24-25%

    Financial Performance

    • Combined Q1 FY27 revenue: INR 2,597 crores, up 20% YoY (proforma).
    • EBITDA: INR 576 crores, up 30% YoY; margin 22.2%.
    • Aster standalone Q1 FY27 revenue: INR 1,311 crores; EBITDA 277 crores; margin 21.1%.
    • Normalised PAT up 39% YoY to ~INR 125 crores; merger costs INR 114 crores (one-time).
    • RoCE improved to 22.6% from 20.7%.

    Operating Update

    • Mature units contribute 73% of revenue; EBITDA margins 30%.
    • Focus units 15% of revenue; revenue up 16%; EBITDA margin +60 bps.
    • Emerging segment revenue up 63% YoY; EBITDA up 240%; margins 12.4% (640 bps).
    • Kasaragod facility breakeven in June 2026 after nine months of operation.
    • Robotics volumes grew ~80% YoY; joint replacements +39%; transplants +19%.
    • Care Hi-Tech earned JCI accreditation; ET Brand of the Year; NABH/Medical Dialogues recognitions.
    • Platform served nearly 8 million patients in 12 months; 39 hospitals, 28 cities, 9 states; 7,400+ clinicians.
    • 159-bed Aster Women & Children block commissioned at Whitefield in Apr 2026.

    Balance Sheet and Cash Flow

    • Combined net debt: INR 1,162 crores as of 30 Jun 2026.
    • Aster net cash: INR 511 crores; Quality Care debt: INR 1,673 crores.

    Capex and Expansion

    • Bed addition target: 4,170 beds in 3-4 years; total beds >15,000; 53% brownfield.
    • 159-bed Aster Women & Children block commissioned at Whitefield.
    • Trivandrum hospital to operate H2 FY27; Hyderabad by Apr 2027; Sarjapur Phase I by H2 FY28.

    Guidance and Outlook

    • EBITDA margin target 24-25% in 2-3 years post-merger.
    • Synergies to deliver 10-15% incremental EBITDA on FY24 pro forma EBITDA; starting this financial year.
    • MVT growth >50%; target mid-single to double-digit contribution over time.
    • Brand unification not decided; multiple brands may continue.

    Q&A Highlights

    • Synergy realization starts this year; target 10-15% incremental EBITDA.
    • Maturity framework defines four categories: mature, focus, emerging, underperforming.
    • Kerala performance strong; Kasaragod break-even in June 2026 after nine months.
    • Trivandrum, Hyderabad, Sarjapur project timelines updated.
    • Brand strategy not decided; plan to leverage market strengths.
    • EBITDA margin target reaffirmed at 24-25% in 2-3 years post-merger.
    • MVT growth agenda; share to mid-single digits then double-digit.
    Read the original filing
  6. GMR Airports Ltd1:21 am IST

    GMR Airports reports Q1FY27 results; revenue up 23%, PAT positive; Nagpur handover completed

    Financial highlights

    • Q1FY27 total income up 23% YoY to INR 4,085 crore.
    • EBITDA up 22% YoY to INR 1,568 crore.
    • PAT stood at INR 148 crore; fourth consecutive positive quarter.

    Portfolio expansion & milestones

    • Nagpur handover completed on 25 Jun 2026; modernization planned.
    • Bhogapuram inaugurated on 1 Aug 2026; commercial operations to commence soon.
    • Mopa on-site packhouse being established to enable incremental perishable exports.

    Strategic MRO agreement

    • GMR Aero Technic signed license with Honeywell for 7 LEAP LRU MRO.
    • Scope includes disassembly, inspection, repair, reassembly, and functional testing.

    Credit rating upgrade

    • CARE upgraded GAL rating to A+ (Positive) from A (Stable) for INR 15bn NCBs and long-term facilities.
    • Short-term rating upgraded to A1+ from A1.

    Q1 airport performance highlights

    • Delhi: 20.4 million passengers in Q1FY27.
    • Hyderabad: 7.1 million passengers; quarterly SPP INR 956.
    • Mopa Goa: 1.16 million passengers; total income INR 126 crore.
    Read the original filing
  7. Pidilite Industries Ltd11:41 pm IST

    Pidilite Q1 FY27: Standalone revenue up 22%, exports weak; margins expand; growth engines advance.

    Financial Performance

    • Standalone revenue: INR 4,237 crores, up 22.2%, volume growth 11.3%.
    • Consolidated revenue: INR 4,541 crores, up 21.3%; EBITDA margin +120 bps; PAT +30.3%.
    • Gross margin 52.5%, down 90 bps YoY; EBITDA margin 26.4%, up 80 bps QoQ.
    • Domestic subsidiaries revenue grew 11.5%; international subsidiaries grew 12%.

    Exports and Pricing

    • B2B exports UVG stood at -8.4% in Q1; overall exports degrew due to geopolitics.
    • Pricing: Consumer & Bazaar price increases near 10% in the quarter.
    • Pricing varies by category and brand; some rebates; inventory carryover occurred.
    • VAM prices fluctuated; management proactive pricing based on replacement margins.

    Growth and Innovations

    • Fevicol X-PER and M-Seal washable described as core innovations.
    • UnoFin progress: green shoots; no fixed target disclosed.
    • Electronics adhesives focus expanding to auto and EV segments; some commercial traction.
    • Waterproofing: Dr. Fixit momentum; projects and retail growth; trained applicators ecosystem.

    Market and Competition

    • Tile adhesives face rising competition from cement and tile manufacturers.
    • Pidilite’s moat: broad plant network, consistent quality, and Total Delivered Cost focus.
    • Waterproofing leadership via Dr. Fixit; emphasis on systems and trained installers.

    Guidance and Outlook

    • Guidance: maintain margin corridor; no change to guidance at this stage.
    • Demand remains robust; management saw no demand impact from pricing actions to date.
    • First-half focus on growth; double-digit underlying volume growth target implied.

    Q&A Highlights

    • Exports expected to rebound as geopolitical conditions stabilize.
    • Pricing increases largely completed by June; demand unchanged.
    • UnoFin progress: green shoots; no fixed target disclosed.
    • Tile adhesives competition; moat from plant network and consistent quality.
    • Margins: corridor maintained; first-half margin expected to be stronger.
    • Electronics adhesives: progress expanding into auto/EV; some commercial traction.
    Read the original filing
  8. Multi Commodity Exchange of India Ltd5:57 pm IST

    MCX Q1 FY27: 85% income rise to INR 752 cr; Silver 100g futures launched; RBI bank-guarantee impact modest

    Financial Performance

    • Total income rose 85% YoY to INR 752 crores in Q1 FY27.
    • Notional Options ADT grew 266% in the quarter.
    • Traded client base doubled to 13.72 lakh in Q1 FY27.
    • Float income for the quarter was around INR 30 crores.
    • Q1 electricity futures ADT approx INR 37 crores; market share about 55%.
    • Employee cost includes a one-time 8-9% rise; not expected to recur.

    Operating Update

    • Silver 100 Grams Futures launched due to market demand.
    • 50+ AMCs now reference MCX bullion price for AUM calculations.
    • Silver Good Delivery norms expanded; domestic silver refiner empanelled.
    • Three more domestic gold refiners empanelled; framework extended across all contracts.
    • Coal Exchange of India incorporated; regulator approvals pending.
    • MCX remains world's largest commodity options exchange; 4th largest by contracts traded.

    Technology & Capacity

    • Tech capacity to handle over 3 billion transactions daily; potential to double capacity.
    • Risk management remains top priority; focus on scale and resiliency.

    Q&A Highlights

    • RBI bank guarantees in force; impact expected modest; cost of funds may rise gradually.
    • SEBI commodity derivatives: timelines on open items not disclosed.
    • Electricity futures: Q1 ADT is INR 37 crores; market share about 55%.
    • 12 new members joined in the quarter.
    • 35 new FPIs; total FPIs around 220.
    • FPI contribution about 2.5% of revenue.
    • Crude/energy volumes volatile; bullion volumes softer in June.
    • 8-10% of daily electricity needs transacted on spot exchanges; derivative growth expected.
    • Competition rising; 12 new members and 35 FPIs joined.
    Read the original filing
  9. Kaynes Technology India Ltd10:21 pm IST

    Kaynes Technology India Q1 FY27: EMS-led 40% revenue rise; OSAT/PCB capex on track amid balance-sheet discipline

    Financial Performance

    • Q1 FY27 revenue 946 crores; YoY growth 40%, EMS-led.
    • EBITDA 147.6 crores; margin 15.6%; YoY EBITDA growth 31%.
    • EMS revenue 854 crores; EMS collections 847 crores; GridCrest revenue 240 crores; GridCrest collections 88 crores.
    • Cash from operations negative ~INR 259 crores; inventory up INR 150 crores.
    • Receivables from leading EV customer below INR 100 crores.
    • Total debt around INR 800 crores; debt-to-equity ~0.3.
    • Profitability to normalize in two quarters as supply-chain costs stabilize.
    • Acquisition of August Electronics completed; North American expansion gaining traction.

    Operating Update

    • OSAT and PCB ramp-up on track; operational by Q3 FY27.
    • PCB capacity fully booked by a large global customer; trials ongoing; vendor code issued.
    • Mitsui-Kaynes Semicon partnership established; access to Japan market.
    • Space tech: first 3U satellite prototype ready; launch mid-next year; ISRO date pending.
    • DRDO and Crio Aerotech to manufacture titanium gas bottles for flight programs.

    Balance Sheet and Cash Flow

    • Receivables from leading EV customer reduced below INR 100 crores.
    • Inventory up by INR 150 crores to support future quarters.
    • Tax rate company ~22–23%; consolidated ~35%.
    • Debt around INR 800 crores; long-term funding not drawn yet.
    • Rolling 12-month view to be shared for working capital metrics.

    Projects and Capex

    • FY26 capex: OSAT 473 crores; PCB 324 crores.
    • FY27 capex target: OSAT 300 crores; PCB 300 crores; EMS 250 crores.
    • Government subsidy OSAT ~INR 170 crores received till July 2026.
    • OSAT-Mitsui partnership significantly milestones; access to Japan market.
    • PCB: trials ongoing; production planned next quarter; large EV customer engaged.
    • In-transit inventory around INR 250 crores.

    Guidance and Outlook

    • FY27 OSAT+PCB revenue target INR 450–500 crores.
    • Market growth was ~17% in Q1; company targets ~2x market growth.
    • OSAT/PCB revenue to start in Q3 and Q4; full-year target remains.
    • Profitability expected to normalize in 2 quarters; margins under pressure from inputs.
    • Cash-positive by year-end FY27.

    Q&A Highlights

    • EMS growth 40%; metering growth 28%; EMS revenue 854 crores; EMS collections 847 crores.
    • OSAT/PCB commercial revenue bookings targeted for Q3 and Q4 FY27.
    • Inventory and receivables elevate CFO decline; steps to mitigate impact discussed.
    • Order book > INR 8,900 crores in system; execution momentum noted.
    • Pricing pressures in PCB and component shortages cited; margins may compress short term.

    Risks and Watchpoints

    • Working capital intensity with higher receivables and inventory; supply-chain lead times.
    • PCB pricing pressures and component shortages; potential margin compression.
    • Strategic option to divest metering service component being evaluated.
    Read the original filing
  10. Inox Wind Ltd12:01 am IST

    INOX Wind & INOX Green Q1 FY27: 4.4 GW backlog, 872 cr revenue, 59% equipment mix; guidance intact.

    Financial Performance

    • INOX Wind Q1 FY27: revenue INR872 cr, EBITDA INR237 cr, PBT INR95 cr, PAT INR64 cr.
    • Cash profit for INOX Wind: INR153 cr in Q1 FY27.
    • Order book stands at ~4.4 GW as of July 2026; equipment share ~59%.
    • NLC India LOA for 200 MW received.
    • MOU for 1.5 GW with INOX Clean; 500 MW firm orders so far.
    • Prototype 4X turbine to be installed August; commercial launch by end FY26.
    • Demerger of the power evacuation infrastructure business from INOX Green into INOX Renewable Solution has been completed as on August 1, 2026.
    • INOX Green Q1 FY27 total income INR101 cr; EBITDA INR57 cr.
    • O&M portfolio stood at 13.3 GW as of June 2026.
    • Wind capacity installed in India 57.4 GW as of June 2026.
    • NCLT Wind World India acquisition completion expected in Q2 FY27.
    • RESCO listing: record date completed; timing to list soon; no forward guidance.
    • ALMM indigenization: 80-90% components; aim 100% by year-end.
    • H2 accounts for 70-75% of annual revenue; guidance remains 75% YoY growth.
    • FY27 annual EBITDA guidance INR600 crores; not a quarterly target.
    • Receivables to improve as pivot to equipment supply; days expected to decline in 3–4 quarters.

    Operating Update

    • Jaipur transformer factory to manufacture 4.9 MVA transformers; expand to 8-20 MVA, 100 MVA+.
    • We own 4 cranes; more to come this financial year.
    • High-value power electronics like inverters, unit substations, capacitor systems; USS commercially launched in FY27.
    • 4 GW wind capacity commissioned in Q1 FY27.
    • Wind World India O&M portfolio stands at ~4.5 GW; FY26 revenue ~INR 580 cr; 5% escalations.
    • Total installed wind capacity in India 57.4 GW as of June 2026; 8-10 GW/year additions expected.

    Guidance and Outlook

    • Full-year revenue growth guidance: 75% YoY; consolidated EBITDA margin 20-22%.
    • H2 typically accounts for 70-75% of annual revenue; guidance remains 75% YoY growth.
    • FY27 EBITDA target INR600 crores annualized after consolidation; impact from Q3 FY27.
    • ALMM indigenization: 80-90% components; aim 100% by year-end.
    • RESCO listing timing to be guided near listing; record date completed.

    Q&A Highlights

    • Pivot to equipment supply causes near-term softness; expects H2 lift and full-year target.
    • 4X model launch by August; commercial activity starting a month later.
    • Receivables to improve as pivot to equipment; days to decline in 3–4 quarters.
    • About 40% third-party orders turnkey; 1.5 GW MOU with INOX Clean; 200 MW LOA from NLC.

    Risks and Watchpoints

    • Execution risk from large backlog and consolidation timeline.
    • Force majeure events could impact timelines; management cited external risks.
    • Silent period limits forward guidance beyond public disclosures.
    • EPC exposure and dependence on group entities; terms are intended to be arm's length.
    Read the original filing